thiophenes has been researched along with Thromboembolism in 140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (4.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (19.29) | 29.6817 |
| 2010's | 107 (76.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, H; Eldahshan, W; Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Pillai, B; Waller, JL | 1 |
| Barrios, V; Escobar, C | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Stiefelhagen, P | 1 |
| Atarashi, H | 1 |
| Buchmueller, A; Buetehorn, U; Gruber, A; Heitmeier, S; Laux, V; Marzec, UM; Perzborn, E; Tinel, H | 1 |
| Nutescu, EA | 1 |
| Kalus, JS | 1 |
| Eikelboom, JW; Weitz, JI | 1 |
| Bauer, KA | 1 |
| Klein, HH | 1 |
| Hagen, G; Hamidi, V; Klemp, M; Reikvam, Å; Ringerike, T | 1 |
| Douketis, J; Liew, A | 1 |
| Rider, EB; Rider, OJ | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Sierra, P; Torres, LM | 1 |
| Alabalik, U; Azboy, I; Bulut, M; Demirtas, A; Necmioglu, NS; Ucar, BY | 1 |
| Accassat, S; Bertoletti, L; Décousus, H; Lega, JC; Merah, A; Mismetti, P | 1 |
| Schellong, S | 1 |
| Lip, GY; Potpara, TS | 1 |
| Bennaghmouch, N; Ten Berg, JM | 1 |
| Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
| Majeed, A; Schulman, S | 1 |
| Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Lee, KH; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Kornej, J; Lip, GY; Potpara, T | 1 |
| Schulman, S | 1 |
| Aramendi, JI; Mestres, CA | 1 |
| Kreutz, R | 1 |
| Greiten, LE; McKellar, SH; Rysavy, J; Schaff, HV | 1 |
| Atkins, D; Baheiry, S; Barrett, CD; Bommana, S; Burkhardt, JD; Chalhoub, F; Di Biase, L; Gangireddy, S; Lakkireddy, D; Mansour, MC; Natale, A; Reddy, V; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Swarup, V; Vallakati, A; Verma, A | 1 |
| Roberts, A | 1 |
| Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P | 1 |
| Albenque, JP; Boveda, S; Combes, N; Combes, S; Hireche, H; Jourda, F; Marijon, E; Morais, J; Providência, R | 1 |
| Groh, C; Passman, R; Yadlapati, A | 1 |
| Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V | 1 |
| Fenger-Eriksen, C; Grove, EL; Münster, AM | 1 |
| Dempfle, CE | 1 |
| Du, S; Harenberg, J; Krämer, R; Krämer, S; Lip, GY; Schulze, A; Wehling, M; Weiss, C; Zolfaghari, S | 1 |
| Ammar, S; Buiatti, A; Deisenhofer, I; Dillier, R; Hessling, G; Hofmann, M; Kaess, B; Kathan, S; Kolb, C; Lennerz, C; Pavaci, H; Reents, T; Semmler, V | 1 |
| Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A | 1 |
| Linkins, LA; Moffat, K | 1 |
| Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P | 1 |
| Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Steurer, J | 1 |
| Camm, AJ; Cappato, R; Ezekowitz, MD; Hemmrich, M; Hohnloser, SH; Kirchhof, P; Klein, AL; Lanius, V; Le Heuzey, JY; Ma, CS; Meng, IL; Scanavacca, M; Talajic, M; van Eickels, M; Vardas, PE; Wildgoose, P | 1 |
| Barnes, GD; Eagle, KA; Froehlich, JB | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L | 1 |
| Bultas, J; Karetová, D | 1 |
| Levasseur-Franklin, KE; Liotta, EM; Naidech, AM | 1 |
| Ambrosoli, A; Cimminiello, C; Compagnone, C; Fanelli, A; Imberti, D; Ottani, F; Tripodi, A | 1 |
| Oberhofer, E | 1 |
| Friedman, RJ; Messerschmidt, C | 1 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Bailleul, E; Borrey, D; Caluwé, R; De Bacquer, D; De Vriese, AS; Emmerechts, J; Van Vlem, B; Vandecasteele, SJ | 1 |
| Arentz, T; Jadidi, A; Lehrmann, H; Park, CI; Pruvot, E; Weber, R; Zimmermann, M | 1 |
| Gehrie, E; Tormey, C | 1 |
| van Eickels, M | 1 |
| Chatelain, B; Devalet, B; Dogné, JM; Douxfils, J; Mani, H; Minet, V; Mullier, F | 1 |
| Bode, C; Kelm, M; Zeus, T | 1 |
| Borchmann, P; Eichhorst, B; Hallek, M; Hellmann, M; Hübel, K; Kochanek, M; Kreuzer, K; Kreuzer, KA; Reiser, M | 1 |
| Connolly, ES; Komotar, RJ; Starke, RM | 1 |
| Oberpichler-Schwenk, H | 1 |
| Abrams, PJ; Emerson, CR | 1 |
| Mantz, J | 1 |
| Samama, CM | 1 |
| Arnaout, L; Bellamy, L; Chabbouh, T; Rosencher, N | 1 |
| Albaladejo, P | 1 |
| Drouet, L | 1 |
| Bounameaux, H | 1 |
| Giugliano, RP; Thomas, D | 1 |
| Darius, H | 1 |
| Bátorová, A | 1 |
| Denaro, V; Longo, UG; Maffulli, N | 1 |
| Heindl, B; Spannagl, M | 1 |
| Roberts, C; Yenna, ZC | 1 |
| Khalabuda, M; McBride, BF; Morell, J; Sullivan, B | 1 |
| Gogarten, W; Pauschert, R; Quante, M | 1 |
| Lopes, RD; Mahaffey, KW; Piccini, JP | 1 |
| Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS | 1 |
| Caglayan, E; Er, F; Erdmann, E; Gassanov, N | 1 |
| Baumhäkel, M; Böhm, M; Schirmer, SH | 1 |
| Jensen, CD; Muller, SD; Partington, PF; Reed, MR; Steval, A | 1 |
| Eikelboom, JW; Eriksson, BI; Quinlan, DJ | 1 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| Bauleo, C; Catapano, G; Formichi, B; Genovesi, D; Giuntini, C; Mannucci, F; Marini, C; Michelassi, C; Monti, S; Prediletto, R | 1 |
| Ajzenberg, N; Dumont, B; Faille, D | 1 |
| Turpie, AG | 3 |
| Kazmi, RS; Lwaleed, BA | 1 |
| Muñoz-Torrero, JF; Zamorano, J | 1 |
| Mega, JL | 1 |
| Di Pasquale, G; Riva, L | 1 |
| Bode, C; Moser, M | 1 |
| Combe, S; Conard, J; Flaujac, C; Horellou, MH; Samamaa, MM | 1 |
| Erdle, S; Harenberg, J; Krämer, R; Marx, S | 1 |
| Lip, GY; Riva, N | 1 |
| Haas, S; Schellong, SM; Spannagl, M | 1 |
| Little, JW | 1 |
| Goel, R; Srivathsan, K | 1 |
| Bode, C; Helbing, T; Moser, M | 1 |
| Crockett, MT; Kavanagh, EC; Moynagh, MR | 1 |
| Lyrer, P; Nedeltchev, K; Seiffge, D | 1 |
| Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC | 1 |
| Brenner, B; Hoffman, R | 1 |
| Giorgi, MA; Miguel, LS | 1 |
| Graf, L; Tsakiris, DA | 1 |
| Gonzalez, MD; Naccarelli, GV | 1 |
| Valle Bernad, R | 1 |
| Nagler, M; Wuillemin, W | 1 |
| Haschke, M | 1 |
| Beyer-Westendorf, J; Donath, L; Günther, KP; Hartmann, A; Knoth, H; Kuhlisch, E; Lützner, J; Radke, OC; Stange, T; Tittl, L; Weiss, N; Werth, S | 1 |
| Fitchett, DH | 1 |
| Ortel, TL | 1 |
| Pawlikowska, Z; Szponar, J | 1 |
| Calaf Alsina, J; Coronado Martín, PJ | 1 |
| Grove, EL; Husted, SE; Kraglund, KL; Modrau, B | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Mohanty, S; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Zhang, Z | 1 |
| Reynolds, MR | 1 |
| Bauer, KA; Fisher, WD; Gent, M; Irwin, MW; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG | 1 |
| Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F | 1 |
| Hampton, T | 1 |
| Haas, S; Kubitza, D | 1 |
| Kakar, P; Lip, GY; Watson, T | 1 |
| Kubitza, D; Laux, V; Misselwitz, F; Perzborn, E | 1 |
| Kubitza, D; Misselwitz, F; Perzborn, E | 1 |
| Gurbel, PA; Tantry, US | 1 |
| Tullio, D | 1 |
| Carniti, E; Fiorini, L; Iezzi, BG; Sbalzarini, G | 1 |
| Verstraete, M | 1 |
| Chapman, DF; Lapchak, PA; Zivin, JA | 1 |
| Cannizzaro, S; Davì, G; Giubilato, A; Strano, A | 1 |
| Katori, M; Kawana, S; Nishiyama, S; Ohta, M | 1 |
| Thilo, D; von Kaulla, KN | 1 |
71 review(s) available for thiophenes and Thromboembolism
| Article | Year |
|---|---|
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Medication Adherence; Morpholines; Renal Insufficiency; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[Factor Xa inhibitor (rivaroxaban and drugs under investigation)].
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New anticoagulants as thromboprophylaxis after total hip or knee replacement.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Outcome Assessment, Health Care; Patient Safety; Premedication; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
The changing face of oral anticoagulants.
Topics: Anticoagulants; Antithrombin Proteins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prodrugs; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2013 |
The perioperative management of new direct oral anticoagulants: a question without answers.
Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Male; Morpholines; Patient Safety; Perioperative Period; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
New oral anticoagulants after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Bleeding and antidotes in new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Administration Schedule; Hemorrhage; Hemostatics; Humans; Morpholines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Advantages and limitations of the new anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Adult; Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2014 |
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Hemostatic Techniques; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Thrombophilia | 2014 |
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2014 |
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; Kidney Function Tests; Morpholines; Perioperative Period; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Models, Animal; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
Periprocedural management of rivaroxaban-treated patients.
Topics: Administration, Oral; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Perioperative Period; Postoperative Complications; Risk; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism | 2015 |
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.
Topics: Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Contraindications; Dabigatran; Hemorrhage; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2015 |
[Hematology 2008].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fibrinolytic Agents; Hematologic Diseases; Hematologic Neoplasms; Hemoglobinuria, Paroxysmal; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
[Rivaroxaban. The first factor Xa inhibitor].
Topics: Animals; Factor Xa Inhibitors; Heart Diseases; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis | 2008 |
Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2009 |
[Perioperative venous thromboembolism prophylaxis: short review and recommendations].
Topics: Adult; Aged; Anticoagulants; Combined Modality Therapy; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Morpholines; Polysaccharides; Postoperative Complications; Preanesthetic Medication; Pulmonary Embolism; Risk Factors; Rivaroxaban; Stockings, Compression; Thiophenes; Thromboembolism; Thrombophlebitis; Vitamin K | 2008 |
[Rivaroxaban (Xarelto): efficacy and safety].
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hematoma, Epidural, Spinal; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Complications; Preanesthetic Medication; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
[Rivaroxaban: mode of action].
Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Molecular Structure; Morpholines; Postoperative Complications; Preanesthetic Medication; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2008 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome | 2009 |
[Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].
Topics: Anticoagulants; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Thromboembolism | 2009 |
[New oral anticoagulants. Consequences for perioperative coagulation diagnostics and therapy].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation Disorders; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Intraoperative Complications; Morpholines; Partial Thromboplastin Time; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism | 2009 |
Thromboprophylaxis after multiple trauma: what treatment and for how long?
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Device Removal; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Multiple Trauma; Polysaccharides; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Vena Cava Filters | 2009 |
[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].
Topics: Administration, Oral; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Orthopedics; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism; Traumatology; Treatment Outcome | 2010 |
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2010 |
New antithrombotic agents--insights from clinical trials.
Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine | 2010 |
[Novel anticoagulants for stroke prevention in atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2010 |
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K | 2011 |
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism | 2011 |
New anticoagulants: how to deal with treatment failure and bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Treatment Failure | 2011 |
Rivaroxaban for the prevention and treatment of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2011 |
Determination of the anticoagulant effects of new oral anticoagulants: an unmet need.
Topics: Administration, Oral; Anticoagulants; Humans; Morpholines; Partial Thromboplastin Time; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Drugs, Investigational; Factor X; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin | 2012 |
Novel oral anticoagulants--key messages for the angiologist.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism | 2012 |
New oral anticoagulants: will they replace warfarin?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivity; Drug Interactions; Factor Xa Inhibitors; Gastritis; Hemorrhage; Humans; Liver; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Newer oral anticoagulant agents: a new era in medicine.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
The novel oral anticoagulants: an update for the interventional radiologist.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Radiography, Interventional; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism | 2012 |
The promise of novel direct oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Warfarin | 2012 |
Anticoagulant treatment: the end of the old agents?
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2012 |
[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Food-Drug Interactions; Hemostasis; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Switzerland; Thiophenes; Thromboembolism | 2012 |
[Clinical pharmacological aspects of new oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Potential role of rivaroxaban in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Intracranial Hemorrhages; Morpholines; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
Perioperative management of patients on chronic antithrombotic therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Middle Aged; Morpholines; Perioperative Care; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Vitamin K | 2012 |
[New anticoagulants--are we prepared?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Multicenter Studies as Topic; Organ Specificity; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Thromboembolism | 2013 |
[Anticoagulant therapy in stroke patients].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Radiography; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2013 |
Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Humans; Injections, Intravenous; Injections, Subcutaneous; Morpholines; Naphthalenes; Oligosaccharides; Polysaccharides; Propionates; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2006 |
Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Drugs, Investigational; Factor Xa; Factor Xa Inhibitors; Glycine; Humans; Morpholines; Piperazines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2007 |
Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
Topics: Administration, Oral; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Humans; Molecular Structure; Morpholines; Patents as Topic; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2007 |
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Bleeding Time; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Orthopedics; Rivaroxaban; Thiophenes; Thromboembolism | 2007 |
Prasugrel, a third generation thienopyridine and potent platelet inhibitor.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Structure-Activity Relationship; Thiophenes; Thromboembolism | 2008 |
[Role of antiaggregant platelet drugs in thromboembolism].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anti-Bacterial Agents; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Humans; Mitral Valve; Platelet Aggregation; Platelet Function Tests; Pyridines; Pyridinolcarbamate; Random Allocation; Sulfinpyrazone; Suloctidil; Thiophenes; Thromboembolism; Ticlopidine | 1981 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases | 1986 |
11 trial(s) available for thiophenes and Thromboembolism
| Article | Year |
|---|---|
Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction.
Topics: Aged; Cilostazol; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Tetrazoles; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K | 2014 |
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2014 |
Dose-finding study of rivaroxaban in hemodialysis patients.
Topics: Administration, Oral; Area Under Curve; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Female; Half-Life; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Morpholines; Renal Dialysis; Rivaroxaban; Thiophenes; Thromboembolism; Thrombophilia | 2015 |
[Rivaroxaban - Largest Study Program with novel oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Europe; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2015 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome | 2009 |
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention o
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Morpholines; Outcome Assessment, Health Care; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Time Factors; Warfarin; Withholding Treatment | 2013 |
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Hemorrhage; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2005 |
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relationship, Drug; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2006 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Blind Method; Heart Valve Prosthesis; Heparin; Humans; Intermittent Claudication; Myocardial Infarction; Prospective Studies; Registries; Thiophenes; Thromboembolism; Thrombophlebitis; Thrombosis; Ticlopidine | 1982 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases | 1986 |
60 other study(ies) available for thiophenes and Thromboembolism
| Article | Year |
|---|---|
Dose-response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Fibrinolytic Agents; Male; Random Allocation; Rats; Rats, Wistar; Recovery of Function; Stroke; Sulfonamides; Thiophenes; Thromboembolism; Tissue Plasminogen Activator | 2019 |
Rivaroxaban prophylaxis too risky for medical inpatients.
Topics: Aged; Anticoagulants; Case-Control Studies; Female; Humans; Inpatients; Length of Stay; Male; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
Topics: Animals; Anticoagulants; Bleeding Time; Blood Coagulation; Blood Coagulation Factors; Factor VIIa; Humans; Male; Morpholines; Primates; Prothrombin Time; Rats; Rats, Wistar; Recombinant Proteins; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
New approaches to reversing oral anticoagulant therapy. Introduction.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Plasma; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1 | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin | 2013 |
Procoagulants for management of bleeding with the new oral anticoagulants.
Topics: Animals; Anticoagulants; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Perioperative management of patients who are receiving a novel oral anticoagulant.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Investigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats.
Topics: Animals; Enoxaparin; Femoral Fractures; Fibrinolytic Agents; Fondaparinux; Fracture Healing; Male; Morpholines; Polysaccharides; Rats; Rats, Sprague-Dawley; Rivaroxaban; Thiophenes; Thromboembolism; Tomography, X-Ray Computed | 2013 |
[Thromboprophylaxis in medical patients: Which modifications with the new oral anticoagulants?].
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Initial experience with rivaroxaban in mechanical valve prosthesis in an animal model.
Topics: Animals; Factor Xa Inhibitors; Heart Valve Prosthesis Implantation; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Transplantation, Heterotopic | 2014 |
[Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Substitution; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model.
Topics: Animals; Factor Xa Inhibitors; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Male; Morpholines; Rivaroxaban; Swine; Thiophenes; Thromboembolism; Transplantation, Heterotopic | 2014 |
Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Perioperative Period; Postoperative Complications; Prospective Studies; Registries; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
Anticoagulation therapy: rivaroxaban is a safe and feasible alternative to warfarin in AF ablation.
Topics: Atrial Fibrillation; Catheter Ablation; Female; Humans; Male; Morpholines; Thiophenes; Thromboembolism | 2014 |
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Electric Countershock; Female; Germany; Hematoma; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Pacemaker, Artificial; Prospective Studies; Prosthesis Design; Prosthesis Implantation; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Prescriptions; Drug Utilization Review; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Portugal; Practice Patterns, Physicians'; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Echocardiography, Transesophageal; Electric Countershock; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Half-Life; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Measurement of rivaroxaban and apixaban in serum samples of patients.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Biological Assay; Case-Control Studies; Chromogenic Compounds; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Serum; Specimen Handling; Thiophenes; Thromboembolism | 2014 |
Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Chi-Square Distribution; Drug Administration Schedule; Female; Germany; Heart Atria; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Odds Ratio; Phenprocoumon; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Sex Factors; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Drug Monitoring; Drug Overdose; Factor Xa; Humans; International Normalized Ratio; Male; Morpholines; Prothrombin Time; Rivaroxaban; Thiophenes; Thromboembolism; Tranexamic Acid; Treatment Outcome | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
[Extended options of anticoagulant treatment in thromboembolism].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2014 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
[Periprocedural management of anticoagulation in patients undergoing atrial fibrillation ablation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Topics: Administration, Oral; Blood Coagulation; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
[Rivaroxaban: a decisive step forward in the management of postoperative thromboembolic disease?].
Topics: Fibrinolytic Agents; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
[Summary and perspectives. Rivaroxaban].
Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney Failure, Chronic; Morpholines; Obesity; Postoperative Complications; Preanesthetic Medication; Rivaroxaban; Thiophenes; Thromboembolism; Thrombophilia; Venous Thrombosis | 2008 |
The novel anticoagulants: entering a new era.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombolytic Therapy; Vitamin K | 2009 |
[New anticoagulants].
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Aftercare; Anticoagulants; Arthroplasty, Replacement, Knee; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Patient Selection; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism | 2009 |
Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Drug Approval; Europe; Factor X; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2009 |
Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Blood Coagulation Disorders; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2010 |
[Prophylaxis of thrombembolic diseases with rivaroxaban].
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; International Normalized Ratio; Metabolic Clearance Rate; Morpholines; Partial Thromboplastin Time; Postoperative Complications; Protein Binding; Prothrombin Time; Rivaroxaban; Thiophenes; Thromboembolism | 2010 |
Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hip Prosthesis; Humans; Knee Prosthesis; Male; Middle Aged; Morpholines; Postoperative Care; Postoperative Complications; Prosthesis-Related Infections; Reoperation; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Tinzaparin | 2011 |
Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension.
Topics: Acid-Base Equilibrium; Aged; Antihypertensive Agents; Blood Gas Analysis; Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Oxygen Consumption; Oxygen Inhalation Therapy; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Thromboembolism; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2013 |
Response to "Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban".
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Morpholines; Thiophenes; Thromboembolism | 2011 |
Vertebral fractures.
Topics: Bone Density Conservation Agents; Humans; Organometallic Compounds; Pulmonary Embolism; Spinal Fractures; Thiophenes; Thromboembolism | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
[Anticoagulation in atrial fibrillation: a new era has begun].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Pharmacologic heterogeneity of new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Approval; Humans; Kidney; Liver; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; United States; United States Food and Drug Administration | 2011 |
[Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Drug Substitution; Factor Xa Inhibitors; Germany; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Rivaroxaban in the prevention and treatment of thromboembolic disorders].
Topics: Evidence-Based Medicine; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2012 |
Rivaroxaban in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2012 |
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; United States; Warfarin | 2013 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Female; Fibrinolytic Agents; Germany; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Kaplan-Meier Estimate; Length of Stay; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Discontinuation of rivaroxaban: filling in the gaps.
Topics: Atrial Fibrillation; Blood Coagulation; Female; Humans; Male; Morpholines; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants show promise.
Topics: Anticoagulants; Clinical Trials as Topic; Factor Xa Inhibitors; Fondaparinux; Glycine; Humans; Morpholines; Piperazines; Polysaccharides; Rivaroxaban; Thiophenes; Thromboembolism | 2006 |
Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Topics: Administration, Oral; Blood Coagulation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2007 |
[Evaluation of platelet aggregation in patients treated with ticlopidine].
Topics: Adult; Aged; Anticoagulants; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Thromboembolism; Ticlopidine | 1984 |
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
Topics: Animals; Cerebral Hemorrhage; Disease Models, Animal; Fibrinolytic Agents; Humans; Intracranial Embolism; Metalloendopeptidases; Phenylalanine; Protease Inhibitors; Rabbits; Stroke; Thiophenes; Thromboembolism; Tissue Plasminogen Activator | 2000 |
Microcirculatory changes during skin allograft rejection and prolongation of survival time by antiplatelet agents.
Topics: Acrylates; Animals; Arterioles; Azathioprine; Blood Platelets; Capillaries; Graft Occlusion, Vascular; Graft Rejection; Graft Survival; Male; Methacrylates; Mice; Mice, Inbred BALB C; Microscopy, Electron; Skin; Skin Transplantation; Thiophenes; Thromboembolism; Thromboxane-A Synthase; Ticlopidine; Transplantation, Homologous; Transplantation, Isogeneic; Venules | 1986 |
[Inhibition of collagen induced aggregation of human thrombocytes using phenyl derivatives of 4-amino-thiopen-3 carbonic acid a new group of synthetic fibrinolytic agents].
Topics: Benzene Derivatives; Blood Platelets; Carbon Dioxide; Collagen; Fibrinolysis; Fibrinolytic Agents; Humans; In Vitro Techniques; Platelet Adhesiveness; Thiophenes; Thromboembolism | 1970 |